Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT07618988
NCT07618988CompletedPhase 4

Safety and Efficacy of Rivaroxaban in Pediatric Patients With Deep Venous Thrombosis

Ain Shams University1 site in 1 country60 target enrollmentStarted: August 3, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
60
Locations
1
Study OverviewStudy DesignEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Prospective interventional randomized controlled trial to assess safety and efficacy of rivaroxaban in pediatric patients with acute deep venous thrombosis.

Detailed Description

Treatment of deep venous thrombotic events in children is based on data obtained in adults with little direct documentation of its efficacy and safety in children. Rivaroxaban is a direct oral anticoagulant which has been approved by FDA in 2021 for the use in pediatric patients with venous thrombosis.

In a randomized controlled trial we will study the safety and efficacy of rivaroxaban use in the pediatric population with acute deep venous thrombosis.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
6 Months to 18 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients from 6 months to less than 18 years of age.
  • •Patients with acute deep venous thrombosis diagnosed based on site-appropriate imaging tools e.g., magnetic resonance venography (MRV) in Cerebral sinus venous thrombosis (CSVT), venous duplex in Central Venous Access Devices (CVAD) related thrombosis or other non-CSVT DVT.
  • •Patients with cancer associated thrombosis are eligible.
  • •Patients with provoked or unprovoked acute VT are eligible.
  • •Patients with first thrombotic event or recurrent VT are eligible.

Exclusion Criteria

  • •Patients with active bleeding
  • •High-risk of bleeding including:
  • •Platelet count of less than 50 x 109/L,
  • •Liver disease associated either a coagulopathy leading to a clinically relevant bleeding risk, or ALT > 5× ULN.
  • •Sustained uncontrolled hypertension defined as systolic and/or diastolic blood pressure > 95th age percentile.
  • •Severe renal impairment (Estimated glomerular filtration rate < 30 mL/min/1.73m2).
  • •Gastrointestinal disease associated with impaired absorption.
  • •Hypersensitivity or any other contraindication listed in the local labelling for Rivaroxaban or comparator treatment.
  • •Patients with rheumatic heart disease or prosthetic heart valves.

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Not Applicable
Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia
NCT07495631Institute of Hematology & Blood Diseases Hospital, China43
Recruiting
Phase 4
Rivaroxaban in Idiopathic Membranous Nephropathy
NCT07404436Beijing Friendship Hospital134
Completed
Not Applicable
Efficacy and Safety of Oral Rivaroxaban in Cerebrosinovenous ThrombosisCerebrosinovenous Thrombosis
NCT07523347Muhammad Aamir Latif75
Not yet recruiting
Not Applicable
Study of Ripertamab in Children With Frequent Relapses or Steroid-Dependent Nephrotic SyndromeFRNS/SDNSRipertamab
NCT07388810Mao Jianhua312
Not yet recruiting
Phase 3
A study to estimate the Efficiency and Safety of Lumateperone as treatment used for irritation related to Autism Spectrum Disorder in Childrens aged 5 to 17 Years.
CTRI/2025/11/097254Intra-Cellular Therapies, Inc.174